What is Interscope?
Interscope Med is at the forefront of developing the EndoRotor®, an innovative interventional device engineered for endoscopic procedures. This next-generation technology is designed to overcome critical challenges in gastroenterology, including endoscopic necrosectomy, incomplete resection, and the management of scarred lesions post-endoscopic mucosal resection. The EndoRotor® aims to augment the capabilities of existing gastrointestinal tools, empowering medical professionals, particularly gastroenterologists, to perform more complex and effective procedures. The company's commitment to advancing therapeutic endoscopy is evident in its focus on pioneering solutions and its engagement in ongoing clinical studies.
How much funding has Interscope raised?
Interscope has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Interscope?
With its recent large-scale, late-stage funding and a major strategic investment, Interscope Med is poised for significant expansion and market penetration. The capital infusion is expected to accelerate the commercialization of the EndoRotor®, support further clinical validation, and enhance the company's operational capacity. This strategic financing signals strong investor confidence in Interscope's technology and its potential to redefine standards in therapeutic endoscopy, positioning the company for sustained growth and leadership in the interventional device market.
See full Interscope company page
